CHMP gives positive opinion on Genmab partner's lung cancer drug
Janssen has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), including a recommendation that its candidate, amivantamab, is conditionally approved in Europe.
by marketwire, translated by catherine brett
Genmab's US partner, Janssen, has received a positive opinion from the CHMP, a committee that is part of the European Medicines Agency, and a recommendation that its candidate receives conditional marketing authorization in Europe for the treatment of non-small cell lung cancer. The dug is called amivantamab, with the commercial name Rybrevant.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen is foreign company of the year in Denmark
For subscribers
New Genmab/Seagen drug will cost up to USD 120,000
For subscribers
Analyst: New Genmab approval shows portfolio potential
For subscribers
